Objective: We aimed to examine the impact of HF on stroke mortality and recurrence (inhospital and post-discharge) in a national stroke cohort from Thailand.
INTRODUCTION
Heart failure (HF) is a recognized risk factor for stroke incidence. The proposed mechanisms underlying the association between HF and increased risk of acute ischemic stroke (AIS) include thromboembolism, cerebral hypoperfusion and small vessel endothelial damage [1] . The association between HF and ICH is less clearly understood, but may relate to antithrombotic therapy being administered in patients with HF, particularly in those with ischaemic cardiomyopathy or AF [2] .
Given the increased stroke incidence in HF patients, hypotheses regarding the influence of pre-existing HF on acute stroke outcomes have been formulated [3] . Previous studies have mainly analysed the association between prevalent HF and post-AIS outcomes, suggesting that it may be associated with higher mortality, longer in-hospital stay and higher disability and recurrence rates [1, [4] [5] [6] [7] [8] . Nevertheless, there have been no studies evaluating the impact of HF on the outcomes of intracerebral haemorrhage (ICH).
In the current study, we sought to determine impact of HF on in-hospital and long-term outcomes (mortality and stroke-specific recurrence) in both major stroke subtypes (AIS and ICH) using a large unselected cohort of stroke patients. Identification of HF as a risk factor for stroke mortality and recurrence may drive further research for the identification and testing of targeted interventions in this population.
METHODS

Data acquisition, case ascertainment and variable coding
We utilised a large observational cohort of consecutively admitted stroke patients from Thailand, drawn from the Universal Coverage (UC) Health Insurance Database. Details regarding the health insurance systems in Thailand can be found in our previous reports [9, 10] . Eligible patients were selected based on the primary diagnosis ICD10 (International Classification of Disease, tenth revision) code recorded in the database. All patients covered by the basic health insurance system ever admitted between October 2004 and September 2015 with a diagnosis of stroke (ICD10 codes I61 (intracerebral haemorrhage), I63 (cerebral infarction), I64 (stroke of undetermined pathology)) were included in this study. Pre-existing co-morbidity, demographic and clinical data were extracted from insurance reimbursement forms using ICD10 codes, detailed in Supplementary Table 1 .
Further admissions with a primary diagnosis of stroke or heart failure (ICD10) and the vital status (date of death if applicable) were recorded. A recurrent stroke event during the follow-up was extracted only if the primary diagnosis of this admission matched the one of the index stroke. In order to account for any new HF diagnoses, we also assessed subsequent hospital admissions, for any changes in the HF comorbidity status. Our study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee in Human Research, Khon Kaen University, Khon Kaen, Thailand.
Inclusion criteria
Inclusion criteria, outcomes of interest (mortality and stroke recurrence) and selection of study variables were all determined a-priori. A total of 615,758 of stroke patients were admitted with primary diagnosis of stroke in the database. After excluding patients younger than 18 (n=1427) or older than 100 (n=43) and those with a missing post-discharge data (n=5419), a total of 608,890 acute stroke patients were included.
For the outcome of stroke recurrence, a further 81,530 patients with prevalent stroke (ICD10 I61, I63, I64) were excluded as well as 128,697 stroke patients who were diagnosed with a stroke of undetermined pathology on their index admission, yielding a cohort of 398,663 first-ever AIS and ICH patients.
Statistical Analysis
All analyses were performed using Stata 14.2 SE (StataCorp 2015), Stata Statistical Software. Due to the large sample size, we chose a P value <0.01 to represent the threshold of statistical significance.
Descriptive Statistics
Stroke type-specific descriptive characteristics were compared between those with prevalent HF and those without at the baseline (index admission in the database) using the independent-sample t-test, Mann-Whitney U test and Chi-squared test, as appropriate.
Analysis of in-hospital mortality
Logistic regressions were used to examine the impact of HF on in-hospital mortality.
We performed analyses for the entire cohort and then stratified by 3 categories (ischemic, haemorrhagic and stroke of undetermined pathology). In order to minimise confounding, we selected covariates according to previous literature [4] [5] [6] [7] [8] to be included in the multivariable logistic regression model. All models were adjusted for age, sex, co-morbidities (hypertension, diabetes mellitus, dyslipidaemia, ischaemic heart disease, valvular disease, atrial fibrillation, other arrhythmias, peripheral vascular disease, cancers, chronic obstructive pulmonary disease, liver disease, anaemia, alcohol-related disorders, neurodegenerative disorders) and admission parameters (fever, hypoglycaemia, hyperglycaemia). Additional sensitivity analyses were performed with adjustments limited to age, sex, cancer and important cardiovascular co-morbidities (hypertension, diabetes, hyperlipidaemia, ischaemic heart disease, valvular heart disease, atrial fibrillation, other arrhythmias, and peripheral vascular disease).
Analysis of long-term post-discharge mortality
To examine the influence of HF on long term mortality, we constructed a survival model based on a flexible parametric regression [11] , using restricted cubic splines (RCS).
The number of internal knots was chosen pragmatically in line with existing literature [12, 13] for our sample size. The proportional hazards (PH) assumption was verified using log negative log plots. The hazard ratios (HR) for the variables which violated the PH assumption were modelled parametrically using the Weibull distribution. When HF was found violate the PH assumption, the HR was modelled using RCSs with 5 internal knots. Models were adjusted for the same confounders as above. Any new HF diagnosis after discharge was included as a binary time-updated variable in the models.
Analysis of long-term post-discharge mortality and recurrence
We constructed 3 transition multi-state models illustrating the typical natural course of a stroke patient (Figure 1 ). This part of the analysis was confined to first-ever stroke cases, given that one of the outcomes of the multi-state model was stroke recurrence. Furthermore, only stroke cases with an identified stroke type (either AIS or ICH) were included. All models were adjusted for any post-discharge incident HF or any of the adjusting comorbidities. . Each transition was modelled using the same protocol as above. The simulation method [12] was employed to estimate the transition probabilities and their 99% confidence intervals. Models were adjusted for the same confounders as above. Additional sensitivity analyses with limited adjustments were performed for transitions 1 and 2.
RESULTS
Patient population & Descriptive Statistics
A flowchart of the patient population is illustrated in Figure 2 . After applying the exclusion criteria, a total of 608,890 stroke cases were included. There were 370,527 (60.85%) cases of AIS, 173,236 (28.45%) cases of ICH and 65,127 (10.70%) cases of stroke with an undetermined pathology.
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The patient characteristics on admission are summarised in Table 1 . Patients had a mean age (SD) of 64.3 (13.7). There were 55.1% males. Patients with pre-existing HF (compared to those without) were older, more likely to be female, spend more time in hospital and have a higher co-morbidity burden across all stroke types. The admission parameters, in-hospital complications and procedures are summarised Table 2 . Patients with pre-existing HF (compared to those without) were more likely to be hypoglycaemic on admission, die in hospital and suffer complications (respiratory failure, pneumonia, sepsis, shock, myocardial infarction, acute kidney injury, pulmonary oedema) during the hospital stay across all stroke types. Patients with HF who were admitted with AIS were more likely to be comatose in-hospital. Patients with HF and AIS were more likely to receive IV thrombolytic treatment than those without. . All between-group differences are statistically significant (P < 0.01) unless otherwise specified.
*Between-group difference not statistically significant (P > 0.01). Table 2 . Admission parameters, in-hospital complications and procedures. All variables are presented as frequency (percentage). All betweengroup differences are statistically significant (P < 0.01) unless otherwise specified.
*Between-group difference not statistically significant (P > 0.01).
Analysis of in-hospital mortality
The results of the multivariable logistic regressions with in-hospital death as the outcome are illustrated in Table 3 . Pre-existing HF was associated with increased odds of inhospital death in all 4 models. Overall, there was an increase in odds, whilst the models fitted separately for each stroke type showed the biggest effect in AIS followed by strokes of undetermined pathology and ICH. Table 3 . Influence of pre-existing Heart Failure on stroke mortality in hospital (results of multivariable logistic regression with no HF as reference category; adjusted for the covariates shown in Supplementary Tables 1 & 2. ). Results in bold are statistically significant (P < 0.01).
Analysis of long-term post-discharge mortality All patients were followed up for a maximum 4108 days for this outcome. Patients with ischaemic, haemorrhagic and undetermined strokes were followed up for a median (95% Analysis of long-term post-discharge mortality and recurrence
For both mortality and recurrence, all patients were followed-up for a maximum of 4108 days. For the mortality outcome, patients with ischaemic and haemorrhagic strokes were followed up for a median (95%CI) of 1583 (1577-1590) and 1802 (1792 -1814) days, respectively. For the recurrent stroke outcome, patients with ischaemic and haemorrhagic strokes were followed up for a median (95%CI) of 875 (862 -887) and 778 (767 -789),
respectively. Median follow-up times and 95% confidence intervals were calculated using the reverse Kaplan-Meier method. Supplementary Figure 3 Figure 3 illustrate the predicted recurrence-free survival, recurrence and mortality probabilities stratified by HF status and stroke type. Supplementary Table 6 illustrates the follow-up post-discharge time when the maximum recurrence probability is reached and its value stratified by HF status and stroke type.
Supplementary Table 7 and Figure 4 
DISCUSSION
Our findings indicate that HF predicts worse mortality outcomes in-hospital and during the long-term follow-up, both before and after stroke recurrence. However, certain important differences between AIS and ICH patients exist. In ICH, HF was not associated with an increased risk of post-discharge death in the very short follow-up (before ~3 months).
After this period, the increased risk of death associated with a HF diagnosis was higher for ICH than AIS patients. Comparing the recurrence-free survival probabilities of ICH patients with and without HF, it becomes apparent that these results may arise from the high mortality of ICH patients in the short-term post-discharge period. Our analysis suggests that HF seems to influence outcomes only after ICH patients stabilize and their mortality rate decreases. It has been well recognized that intracranial haemorrhagic events can cause serious cardiac side-effects [14] , including cardiac failure. It may thus be that ICH patients with co-morbid HF may be more likely to suffer cardiac decompensation, leading to an increased risk of death.
Our statistical models yielded no association between HF and AIS recurrence. HF was associated with recurrent ICH only within the first 18 months. This revealed that there may be a 'window' within the first 30 months post-discharge when HF patients with ICH have an increased risk of both recurrent stroke and death, after which only the mortality risk persists.
It is possible that the observed changes in the significance of ICH recurrence, occurring at around 2.5 years post-discharge, may be attributable to the contribution of more severe stroke types. As the patients with a more severe clinical presentation leave the cohort (as they die) at ~ 2 years post-discharge, it is likely that this effect diminishes and thus the HR becomes insignificant. Nevertheless, in the absence of an objective measure of stroke severity, our hypothesis cannot be tested. Future work focusing on the impact of HF on stroke outcomes should therefore account for both stroke and HF severity.
The relationship between HF and post-AIS mortality has been previously studied [1, [4] [5] [6] [7] [8] [14] [15] [16] [17] [18] [19] [20] , showing that the co-existent HF increases the mortality risk both in-hospital [5] [6] [7] [8] 15] and after discharge [4] [5] [6] [7] [8] [16] [17] [18] [19] [20] .
A previous meta-analysis [1] suggests that there is a two-fold increase in the risk of AIS recurrence associated with co-morbid HF. Nevertheless, our results appear to show that patients with HF were not at a higher risk of recurrent AIS than those without. Whilst this is based on observational data, our results appear to point into a similar direction as the recent COMMANDER HF trial, which showed that rivaroxaban anticoagulation was not associated with a reduction in the rate of stroke in heart failure patients [21] .
The data regarding the influence of co-morbid HF on post-ICH mortality is scarce [22] . We have shown that the impact of HF on ICH mortality is substantial, with a two-fold mortality risk increase. Since previous studies on ICH recurrence [23, 24] have only focused on the radiological characteristics of the primary event, we are the first to evaluate the influence of co-morbid HF on ICH recurrence in the long-term.
The mechanisms behind the association between HF and ICH recurrence remain nevertheless unclear. It may simply be that HF patients are more likely to receive antithrombotic therapy [2] due to underlying co-morbidities (coronary artery disease, valvular disease and atrial fibrillation), thus rendering these patients more prone to haemorrhagic events [25, 26] . Whilst we were unable to explore this further in the current analysis, our results suggest that caution should be exerted with HF management strategies that may cause haematological disturbances in patients with ICH. A balanced risk-vs-benefit approach may thus be desirable in the first 18 months after the acute event.
Our study has several strengths. We have utilized a prospectively-identified multicentre national cohort, thus minimising the potential selection bias. To the best of our knowledge, this is the first study to differentially analyse the relationship between HF and long-term outcomes of AIS and ICH. Our analysis provides granular insight regarding the dynamic nature of the HF-associated increased risk of death and event recurrence. This has so far not been possible in previous studies. By employing multi-state survival methods and modelling the transition probabilities using flexible parametric techniques, we have managed to overcome the limitations of classical survival analysis models [27] . Furthermore, we have also estimated the absolute probabilities of recurrence-free survival, recurrence and death for both AIS and ICH, stratified by the HF status. By updating any post-discharge HF diagnoses in our statistical models, we have more accurately captured the real distribution of this comorbidity in our population. We have for the first time illustrated the time-varying nature of the excess mortality and recurrence risk associated with co-morbid HF in both stroke types.
We are the very first study assessing the relationship between HF and cerebrovascular disease in Asians, population in which stroke epidemiology is markedly different [28, 29] .
We acknowledge certain limitations. Having based all of our analyses on insurance data, case ascertainment was performed using ICD10 codes. We thus lack data regarding stroke severity and the clinical characteristics of HF (severity, ejection fraction, aetiology).
Given that stroke severity may be an important determinant of post-stroke prognosis, it may be not be possible to confirm a direct relationship between HF and adverse stroke outcomes.
Furthermore, our data may not be applicable in other populations and different healthcare systems. It is important to underline that our cohort was significantly younger than Western stroke cohorts [5] [6] [7] [8] . Nevertheless, the pathophysiological link between HF and stroke is unlikely to be significantly different, highlighted by the fact that our results are concordant with previous literature. Our cohort enrolment occurred over 12 years and time-dependent differences may exist in case ascertainment and management. Nevertheless, this remains one of the inherent limitations of long-term follow-up studies. Our data did not include any information regarding post-discharge medications or ancillary procedures and we were thus unable to explore the effect of HF therapy or antithrombotic medication on outcomes.
Finally, we were not able to evaluate the causes of death.
In summary, we report for the first time the impact of co-morbid HF on the clinical trajectories of acute stroke patients, providing stroke-type specific prognostic information.
We have shown that co-morbid HF significantly increases the risk of in-hospital and postdischarge death in both AIS and ICH, with the effect on ICH patients being more 
Supplementary Figure 1.
The hazard ratio (HR) calculated for patients with intracerebral haemorrhage and co-morbid heart failure (with no heart failure as the reference category). The solid line represents the point estimate, whilst the shaded area is bound by the extreme values of the 99% confidence interval Supplementary Figure 4 . Predicted probabilities of being in each state (recurrence-free survival, recurrence and mortality) stratified for HF status. Separate calculations were performed for each stroke type. The solid line represents the point estimates in patients without co-morbid heart failure, whilst the dashed line represents the point estimates in patients with co-morbid heart failure. The shaded areas are bound by the extreme values of the 99% confidence interval for each respective point estimate.
